Search

Your search keyword '"Smilakou, Stavroula"' showing total 11 results
Start Over Author "Smilakou, Stavroula"
11 results on '"Smilakou, Stavroula"'

1. Candida auris in Greek healthcare facilities: Active surveillance results on first cases and outbreaks from eleven hospitals within Attica region

Author

Politi, Lida, Vrioni, Georgia, Hatzianastasiou, Sofia, Lada, Malvina, Martsoukou, Maria, Sipsas, Nikolaos V., Chini, Maria, Baka, Vasiliki, Kafkoula, Eleni, Masgala, Aikaterini, Pirounaki, Maria, Michailidis, Christos, Chrysos, Georgios, Zarkotou, Olympia, Mamali, Vasiliki, Papastamopoulos, Vasileios, Saroglou, Georgios, Pournaras, Spyros, Meletiadis, Joseph, Karakasiliotis, Ioannis, Karachalios, Stefanos, Smilakou, Stavroula, Skandami, Vasiliki, Orfanidou, Maria, Argyropoulou, Athina, Tsakris, Athanassios, and Kontopidou, Flora

Published
2024
Full Text
View/download PDF

2. Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma.

Author

Diamantopoulos, Panagiotis T., Kontandreopoulou, Christina-Nefeli, Stafylidis, Christos, Vlachopoulou, Dimitra, Smilakou, Stavroula, Patsialos, Iraklis, Syriopoulou, Stavroula, Gkikas, Alexandros, Athanasopoulos, Eleftherios N., Vogiatzakis, Anastasios, Panousi, Eleni, Kyriakakis, Georgios, Anastasopoulou, Amalia, Mantzourani, Marina, and Labropoulou, Vassiliki

Subjects
HERPES zoster vaccines, CHRONIC lymphocytic leukemia, MULTIPLE myeloma, IDIOPATHIC thrombocytopenic purpura, VARICELLA-zoster virus, HERPES zoster
Abstract

Background/objectives: Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are susceptible to viral infections, including varicella-zoster virus (VZV) reactivation due to both disease-related and treatment-induced immunosuppression. The recombinant adjuvanted herpes zoster vaccine (RZV) has shown high efficacy in immunocompetent adults, but immunogenicity data in CLL and MM patients are limited. This study evaluates the immunogenicity and safety of RZV in this population. Methods: Patients with CLL and MM vaccinated with RZV (administered in two doses at least one month apart) were included in the study. Pre- and post-vaccination anti-VZV IgM and IgG antibody levels were measured to assess immunogenicity, and adverse events (AEs) were captured for safety evaluation. Results: Seventy-eight patients received both vaccine doses, and 71 had post-vaccination samples. Most of the patients were IgM seronegative and IgG seropositive before vaccination. Pre-vaccination IgG levels were higher in CLL patients compared to MM patients (p = 0.001), while post-vaccination IgG levels significantly increased in both CLL (p < 0.0001) and MM (p < 0.0001) patients. In actively treated CLL patients, pre-vaccination IgG levels were significantly lower than in not actively treated patients (p = 0.002). Post-vaccination IgG levels were lower in MM patients receiving antiviral prophylaxis concurrently with the vaccination (p = 0.013). AEs were reported in 49.4% of patients after the first dose and 48.7% after the second dose, mostly mild (local or low-grade systemic). One case of immune thrombocytopenia was noted. Conclusions: RZV demonstrated strong immunogenicity and acceptable safety in CLL and MM patients, significantly boosting IgG levels, even in actively treated or heavily pretreated patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study

Author

Skoutelis, Athanasios, primary, Pefanis, Angelos, additional, Tsiodras, Sotirios, additional, Sipsas, Nikolaos V., additional, Lelekis, Moyssis, additional, Lazanas, Marios C., additional, Gargalianos, Panagiotis, additional, Dalekos, George N., additional, Roilides, Emmanuel, additional, Samonis, George, additional, Maltezos, Efstratios, additional, Hatzigeorgiou, Dimitrios, additional, Lada, Malvina, additional, Metallidis, Symeon, additional, Stoupis, Athena, additional, Chrysos, Georgios, additional, Karnesis, Lazaros, additional, Symbardi, Styliani, additional, Loupa, Chariclia V., additional, Giamarellou, Helen, additional, Kioumis, Ioannis, additional, Sambatakou, Helen, additional, Tsianos, Epameinondas, additional, Kotsopoulou, Maria, additional, Georgopali, Areti, additional, Liakou, Klairi, additional, Perlorentzou, Stavroula, additional, Levidiotou, Stamatina, additional, Giotsa-Toutouza, Marina, additional, Tsorlini-Christoforidou, Helen, additional, Karaiskos, Ilias, additional, Kouppari, Georgia, additional, Trikka-Graphakos, Eleftheria, additional, Ntrivala, Maria-Anna, additional, Themeli-Digalaki, Kate, additional, Pangalis, Anastasia, additional, Kachrimanidou, Melina, additional, Martsoukou, Maria, additional, Karapsias, Stergios, additional, Panopoulou, Maria, additional, Maraki, Sofia, additional, Orfanou, Anagnostina, additional, Petinaki, Efthymia, additional, Orfanidou, Maria, additional, Baka, Vasiliki, additional, Stylianakis, Antonios, additional, Spiliopoulou, Iris, additional, Smilakou, Stavroula, additional, Zerva, Loukia, additional, Vogiatzakis, Evangelos, additional, Belesiotou, Eleni, additional, and Gogos, Charalambos A., additional

Published
2017
Full Text
View/download PDF

6. Diagnosis of Helicobacter pylori infection by HpSA test

Author

Zaffoni, Elisa, Caselli, Michele, Trevisani, Lucio, Sartori, Sergio, Alvisi, Vittorio, Plebani, Mario, Basso, Daniela, Archimandritis, Athanasios, Giontzis, Apostolos, Smilakou, Stavroula, Tzivras, Michalis, and Davaris, Panagiotis

Subjects
Helicobacter pylori -- Diagnosis
Published
1999

7. Changes in the rates and population structure of methicillin-resistant Staphylococcus aureus(MRSA) from bloodstream infections: A single-centre experience (2000–2015)

Author

Nikolaras, Georgios P., Papaparaskevas, Joseph, Samarkos, Michael, Tzouvelekis, Leonidas S., Psychogiou, Mina, Pavlopoulou, Ioanna, Goukos, Demetrios, Polonyfi, Katerina, Pantazatou, Aggeliki, Deliolanis, Ioannis, Smilakou, Stavroula, and Daikos, George L.

Abstract

•Rate of MRSA bloodstream infections is declining.•The pandemic HA-MRSA clone ST239-III (CC8) has been eliminated.•CA-MRSA ST80-IV causes bloodstream infections in hospitalised patients.•There was an upward trend in the prevalence of HA-MRSA ST5-II (CC5).

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results